Skip to main content

View full-text article in PMC

. Author manuscript; available in PMC: 2015 May 1.

Published in final edited form as: Stat Biopharm Res. 2014 May 27;6(2):185–197. doi: 10.1080/19466315.2014.906365

Table 6.

MTD Recommendation and in-trial allocation for scheme V

	Group 1						Group 2
	d₁	d₂	d₃	d₄	d₅	d₆	d₁	d₂	d₃	d₄	d₅	d₆
	Scenario A
	Group 1						Group 2
	Ratio of N₁/N₂ = 20/12
R_i(d_k)	.07	.23	.31	.35	.45	.57	.07	.23	.31	.35	.45	.57
Prop (d_i)	17	42	26	13	2	0	21	41	31	6	1	0
Prop (pts)	24	27	28	16	5	0	17	40	33	8	1	0
	Ratio of N₁/N₂ = 16/16
Prop (d_i)	20	35	28	15	3	0	20	45	28	7	1	0
Prop (pts)	25	24	28	17	6	0	18	40	31	9	1	0
	Scenario B
	Ratio of N₁/N₂ = 20/12
R_i(d_k)	.08	.20	.35	.50	.70	.80	.01	.05	.18	.40	.55	.70
Prop (d_i)	19	51	28	2	0	0	1	23	68	8	0	0
Prop (pts)	25	35	31	9	5	0	4	33	57	5	0	0
	Ratio of N₁/N₂ = 16/16
Prop (d_i)	19	49	29	4	0	0	0	18	74	8	0	0
Prop (pts)	26	31	31	10	2	0	3	30	61	7	0	0
	Scenario C
	Ratio of N₁/N₂ = 20/12
R_i(d_k)	.02	.19	.31	.45	.51	.63	.03	.05	.11	.21	.39	.50
Prop (d_i)	9	47	39	5	0	0	0	11	60	27	2	0
Prop (pts)	17	32	37	12	3	0	2	21	60	16	0	0
	Ratio of N₁/N₂ = 16/16
Prop (d_i)	12	42	38	8	1	0	0	8	56	34	3	0
	18	29	37	14	3	0	2	17	58	20	2	0